Cons of GLP-1: The Complete Guide to Risks, Side Effects & Downsides
The cons of GLP-1 medications come down to four realities: (1) GI side effects are very common (reported by 73% of Wegovy users and 56% of Zepbound users in trials), (2) cost and coverage remain unpredictable, (3) stopping often leads to significant weight regain, and (4) rare but serious risks exist — including gallbladder disease, pancreatitis, and dehydration-related kidney injury.
This guide ranks each downside by likelihood, severity, red flags, and what to do — so you can decide whether the trade-offs are acceptable for your situation.
Disclosure: We may earn commissions when you sign up through our links. This doesn't affect our rankings or editorial analysis. Learn more
Medical note: Educational only — not medical advice. If you have urgent symptoms, seek emergency care.
Quick Answer
- Most common con:GI side effects (nausea, vomiting, diarrhea, constipation) — often improve after dose stabilization
- Biggest long-term con:Weight regain is common after stopping — plan for ongoing management
- Highest-stakes rare cons:Pancreatitis, gallbladder disease, severe dehydration/kidney injury, vision emergencies
- Practical con:Cost + access + counterfeit/compounded risks require careful navigation
Contraindications: personal/family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.
Jump to What You Care About
GLP-1 Cons at a Glance: The Downsides Map
Percentages below come directly from FDA prescribing information.
| Con | How Common? | Severity | Red Flags | What to Do |
|---|---|---|---|---|
| GI side effects (nausea, vomiting, diarrhea, constipation) | Very common. Wegovy: 73% reported GI adverse reactions (vs 47% placebo). Zepbound: 56% (vs 30% placebo). | Usually mild to moderate; can be severe | Can't keep fluids down; severe dehydration; severe belly pain | Slower titration, smaller meals, hydration; same-day clinician call if persistent |
| Cost & access | Common barrier (coverage varies; self-pay programs change frequently) | High impact | Coverage denial; shortages; tempted by "too cheap" products | Verify coverage + backup plan; avoid unapproved sources |
| Weight regain after stopping | Common in trials. Semaglutide withdrawal: regained ~2/3 of prior loss. Tirzepatide withdrawal: regained ~14% body weight. | High impact | N/A | Plan maintenance before starting; expect long-term management |
| Gallbladder disease (stones/inflammation) | Uncommon but real. Wegovy: cholelithiasis 1.6% vs 0.7% placebo; cholecystitis 0.6% vs 0.2%. Zepbound: cholecystitis 0.7% vs 0.2%; cholecystectomy 0.2% vs 0%. | Serious | Right-upper belly pain after meals; fever; jaundice | Prompt clinician evaluation; urgent care if severe |
| Pancreatitis | Rare, but labeled warning | Urgent | Severe abdominal pain (often radiating to back) + vomiting | Emergency evaluation; don't take another dose until cleared |
| Kidney injury (often dehydration-related) | Uncommon | Serious | Very low urine output; confusion; severe dehydration | Medical evaluation; treat dehydration early |
| Thyroid C-cell tumor boxed warning (MTC/MEN2) | Eligibility issue (contraindication if personal/family MTC or MEN2) | High-stakes | History of MTC/MEN2; neck lump; hoarseness | Do not use if contraindicated; discuss thyroid history with prescriber |
| Birth control interaction (tirzepatide only) | Specific to tirzepatide: may reduce oral contraceptive efficacy | Moderate | Unintended pregnancy risk | Use non-oral or barrier method for 4 weeks after start & each dose increase |
| Surgery/anesthesia planning | Situational | Moderate to serious | Active GI symptoms near procedure | Tell anesthesia team; follow risk-based guidance |
Likelihood terms reflect FDA clinical trial reporting where available; real-world rates vary by dose, titration speed, and individual risk factors. Sources: FDA Wegovy label, FDA Zepbound label, FDA Saxenda label.
Start Here Based on Your Situation
Considering GLP-1 for weight loss?
Start with Decision Framework + Who Should Avoid GLP-1
Already taking it and feeling sick?
Start with Red Flag Checklist + GI Side Effects
Worried about long-term risks?
Start with Serious Risks + The Unknowns
Thinking about stopping?
Read What Happens When You Stop first
Seeing compounded/counterfeit/"patch" products?
Read Scams & Unsafe Alternatives before buying anything
What GLP-1 Medications Actually Are
GLP-1 receptor agonists are prescription medications that affect appetite signals, blood sugar, and stomach emptying. For a deeper dive, see our What Is GLP-1 guide. The main products generating discussion:
Semaglutide products:
- Wegovy (weight management — injection; oral tablets FDA-approved Dec 2025)
- Ozempic (type 2 diabetes)
- Rybelsus (oral tablet for diabetes)
Tirzepatide products (GIP/GLP-1 dual agonist):
- Zepbound (weight management)
- Mounjaro (type 2 diabetes)
Liraglutide products:
- Saxenda (weight management)
- Victoza (type 2 diabetes)
Two critical points:
First, FDA-approved GLP-1 medications require a prescription and come with official prescribing information. If a product can't provide these, treat it as unverified.
Second, compounded GLP-1 products can be legitimate in narrow scenarios, but the FDA has published ongoing concerns about quality, dosing errors, and adverse events.
GI Side Effects: The Most Common Con
GI side effects are common enough that you should assume you'll need a management plan, especially during dose escalation.
The Real Numbers (From FDA Labels)
Wegovy (semaglutide):
- 73% reported GI adverse reactions (vs 47% placebo)
- Nausea: 44% (vs 16% placebo)
- Vomiting: 25% (vs 6% placebo)
- Diarrhea: 30% (vs 16% placebo)
- Constipation: 24% (vs 11% placebo)
Zepbound (tirzepatide) — FDA label (dose-dependent):
- Nausea: 25–29% (vs 8% placebo)
- Diarrhea: 19–23% (vs 8% placebo)
- Constipation: 11–17% (vs 5% placebo)
- Vomiting: 8–13% (vs 2% placebo)
- GI events typically occur during escalation and decrease over time
Saxenda (liraglutide):
- Nausea: 39.3% (vs 13.8% placebo)
- Diarrhea: 20.9% (vs 9.9% placebo)
- Constipation: 19.4% (vs 8.5% placebo)
Why This Happens
GLP-1 medications intentionally slow gastric emptying and increase satiety signals. That mechanism produces nausea, fullness, and sometimes vomiting or constipation — especially when doses are increasing.
The "Don't Suffer Unnecessarily" Playbook
What tends to help:
- Smaller meals, eaten slowly
- Lower-fat intake during escalation phases
- Intentional hydration (appetite suppression often means drinking less)
- Slower titration if symptoms are severe — ask your prescriber
If you're struggling, the answer is usually dose adjustment with your prescriber — not white-knuckling it for months.
Red Flag Checklist
Print this. Put it somewhere visible.
Call Your Clinician Same Day If You Have:
- Vomiting lasting more than 24 hours
- Signs of dehydration (very dark urine, dizziness, feeling faint)
- Severe or persistent diarrhea
- New or worsening abdominal pain
Seek Urgent or Emergency Care Now If You Have:
- Severe abdominal pain (especially radiating to your back) + vomiting — pancreatitis concern
- Jaundice (yellow eyes/skin) or severe right-upper abdominal pain after eating — gallbladder concern
- Sudden vision loss or "curtain" over vision — eye emergency
- Thoughts of self-harm — call/text 988 (U.S.). If outside the U.S., contact your local emergency number or crisis line
Serious Medical Risks: Rare But Real
Most GLP-1 side effects are unpleasant but manageable GI symptoms. The serious risks are less common, but they're what "informed consent" actually means.
Pancreatitis
This is a labeled warning for all GLP-1 weight management medications. If pancreatitis is suspected, prescribing information instructs discontinuation and prompt evaluation.
What it feels like: Severe abdominal pain (often radiating to the back) with nausea and vomiting.
What to do: This is urgent. Seek emergency evaluation.
Gallbladder Disease
From FDA prescribing information:
- Wegovy: Cholelithiasis (gallstones) 1.6% vs 0.7% placebo; cholecystitis (inflammation) 0.6% vs 0.2%.
- Zepbound: Cholecystitis 0.7% vs 0.2% placebo; cholecystectomy (removal) 0.2% vs 0%.
What it feels like: Pain in the right upper abdomen after eating, fever, nausea, or jaundice.
What to do: Prompt medical evaluation. Surgery may be needed.
Acute Kidney Injury
Both Wegovy and Zepbound labeling emphasize kidney injury risk in the setting of dehydration from GI effects. This is largely preventable.
What it looks like: Very low urine output, severe dizziness, confusion.
What to do: Medical evaluation. Prevention means hydrating aggressively and managing GI symptoms early.
Thyroid C-Cell Tumor Boxed Warning
All GLP-1 weight management medications carry contraindications for people with:
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
This isn't something to "monitor through" — it's an eligibility issue. Discuss any thyroid history with your prescriber before starting.
Hypoglycemia
GLP-1 medications can increase hypoglycemia risk when combined with insulin or sulfonylureas. Prescribers typically adjust other diabetes medications when adding GLP-1.
Eye Risks: Label Warnings vs. Emerging Signals
Two different "eye risk" conversations get mixed together online. The distinction matters.
Diabetic Retinopathy (Established Label Warning)
Wegovy labeling notes diabetic retinopathy reporting and the concept that rapid glucose improvement can temporarily worsen existing retinopathy in people with diabetes.
What to do: If you have diabetic retinopathy, your provider should monitor your eyes when starting treatment.
NAION / Optic Nerve Disorders (Emerging Observational Data)
- A 2024 cohort study (JAMA Ophthalmology) reported an association between semaglutide prescription and NAION. This is an association, not proof of causation.
- A 2025 target-trial emulation found semaglutide and tirzepatide associated with higher risk of NAION and other optic nerve disorders, with overall low absolute risk.
The rule: Sudden vision loss is always an emergency, regardless of cause.
Mental Health: What FDA Says
FDA's preliminary evaluation did not find evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. However, FDA continues monitoring because adverse event reports exist and the topic is high-stakes.
Practical takeaway: If you have a history of depression, anxiety, or eating disorder behaviors, starting GLP-1 should include a monitoring plan — not casual dismissal of mental health concerns. If mood worsens or self-harm thoughts appear, contact a clinician immediately.
Drug Interactions: The One You Cannot Miss
Tirzepatide + Oral Contraceptives
Zepbound labeling advises switching to a non-oral method or adding a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation.
If you're of reproductive age and considering tirzepatide, this is one of the most important cons to understand before starting.
Why Interactions Happen
Delayed gastric emptying can change absorption timing of oral medications. Labels advise caution and monitoring for narrow therapeutic index drugs.
Pregnancy and Breastfeeding: Plan Ahead
GLP-1 weight management medications are not recommended during pregnancy.
Wegovy (Specific Timing)
Wegovy labeling instructs discontinuing at least 2 months before planned pregnancy due to the medication's long half-life.
Other GLP-1 Medications
For tirzepatide and liraglutide, follow product labeling and clinician guidance for pregnancy planning. The key concern with tirzepatide is the oral contraceptive interaction discussed above.
Breastfeeding
Not recommended due to lack of human data.
Surgery and Anesthesia: Updated Risk-Based Guidance
Multi-society guidance (October 2024) emphasizes that most patients can continue GLP-1 medications before elective surgery, using a risk-based approach. Higher-risk patients — those with significant GI symptoms, in dose escalation, on higher doses, or with other factors affecting stomach emptying — may need modified preparation.
What to do: Always tell your anesthesia team what you're taking, your last dose date, and whether you're currently escalating doses.
What Happens When You Stop: The Regain Reality
Stopping GLP-1 is a major con because weight regain is the norm, not the exception.
The Trial Data
STEP 1 Extension (semaglutide):
Participants who stopped semaglutide regained approximately two-thirds of their prior weight loss within 1 year. Cardiometabolic improvements also moved back toward baseline.
SURMOUNT-4 (tirzepatide):
After randomization, participants switched to placebo experienced approximately 14% body weight regain, while those continuing treatment maintained or extended their losses.
What This Implies
For many people, obesity behaves like a chronic condition requiring chronic management. If you're starting GLP-1 without asking "What's my plan if I have to stop?" you're walking into one of the most predictable downsides without a strategy.
Muscle Loss and Body Composition
Weight loss typically includes some lean mass (muscle) loss. This isn't unique to GLP-1, but it matters.
What the Studies Show
- Semaglutide STEP body composition analysis: Lean mass decreased, but fat mass decreased more, and overall body composition proportions improved.
- Tirzepatide DXA substudy: About 25% of weight lost was lean mass; semaglutide substudies also show measurable lean mass reductions alongside fat loss. The ratio varies by individual and study population.
Why This Matters
Less muscle means lower metabolic rate, reduced strength, and increased fall risk (especially in older adults). And critically: when weight regains, it returns primarily as fat.
What Helps
- Resistance training 2-4 times weekly (the most effective intervention)
- Adequate protein (discuss targets with clinician/dietitian)
- Avoid over-restricting calories (accelerates muscle loss)
"Ozempic Face" and Cosmetic Changes
Rapid weight loss from any cause can produce visible facial changes: hollowed cheeks, more prominent wrinkles, sagging skin. This gets called "Ozempic face" but isn't unique to GLP-1 — it's rapid facial fat loss.
Hair Loss
Some people experience temporary hair thinning. This is likely telogen effluvium — a stress response to rapid weight change — and usually resolves. Adequate protein may help.
Cost and Access
Medicare: The Nuance Most People Miss
A new cardiovascular indication for Wegovy created a pathway where some Medicare beneficiaries may qualify for Part D coverage for that indication (not "weight loss coverage"). Whether you qualify depends on your specific situation.
The takeaway: Don't assume "Medicare never covers GLP-1" or "Medicare covers GLP-1 for weight loss." Reality depends on the approved indication and individual circumstances.
Self-Pay Programs
- Zepbound: LillyDirect/Walmart direct-to-consumer pricing has been announced (program terms apply)
- Wegovy: NovoCare savings programs exist (terms change)
If you might need GLP-1 long-term, cost isn't a side note — it's a primary decision variable. See our cheapest semaglutide pricing guide for current options, or learn how to get approved without insurance.
Scams and Unsafe Alternatives
The fastest way to turn GLP-1 into a genuinely dangerous decision is to buy something that isn't actually the regulated medicine.
FDA's Core Warnings
The FDA has ongoing concerns about unapproved GLP-1 drugs, including:
- Quality and ingredient issues
- Adverse events from compounded semaglutide and tirzepatide (likely underreported)
- Dosing errors with compounded semaglutide injectables — some requiring hospitalization (July 2024)
- Counterfeit Ozempic found in the U.S. drug supply chain (December 2025)
"GLP-1 Patches"
There are no FDA-approved GLP-1 patches. Any "patch" marketed online for weight loss is unapproved and unverified. Treat these as high-risk for scams.
Safe Sourcing Checklist
Only consider a product if it:
- Requires a prescription from a licensed provider
- Comes from a licensed pharmacy
- Includes legitimate labeling and handling instructions
- Arrives properly refrigerated (for injectables)
- Is NOT labeled "for research use only"
- Doesn't have a price that seems impossibly low
Lifestyle and Quality of Life Cons
Even when medical risks are low, many people stop GLP-1 because of day-to-day friction:
- Injection management: Weekly (or daily for Saxenda), needle anxiety, travel refrigeration
- Changed relationship with food: Less enjoyment, social eating challenges, food aversions
- The mental load: Remembering doses, navigating refills and prior authorizations, dealing with shortages
- "Forever medication" psychology: Accepting potential lifelong treatment, feeling dependent
These aren't trivial — they're often the difference between short-term and sustained use.
Medication Comparison Table
| Factor | Semaglutide (Wegovy/Ozempic/Rybelsus) | Tirzepatide (Zepbound/Mounjaro) | Liraglutide (Saxenda) |
|---|---|---|---|
| GI adverse reactions | 73% (Wegovy trials). Nausea 44%, vomiting 25%, diarrhea 30% | 56% pooled. Nausea 25-29% (dose-dependent) | Nausea 39.3%. Diarrhea 20.9% |
| Dosing | Weekly injection (tablets FDA-approved Dec 2025) | Weekly injection | Daily injection |
| Oral contraceptive issue | Not a prominent label warning | Yes — add barrier/non-oral for 4 weeks after start & each escalation | Not a prominent label warning |
| Gallbladder signal | Cholelithiasis 1.6% vs 0.7%. Cholecystitis 0.6% vs 0.2% | Cholecystitis 0.7% vs 0.2%. Cholecystectomy 0.2% vs 0% | Listed in labeling |
| Medicare pathway | CV indication may enable Part D coverage for qualifying patients | No similar pathway currently | No similar pathway |
Who Should NOT Take GLP-1 Medications
Absolute Contraindications (Weight Management)
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Prior serious hypersensitivity to the medication
- Pregnancy (weight management indication)
Strong Caution — Requires Careful Discussion
- History of pancreatitis
- Significant gallbladder disease history
- Severe GI disease or severe gastroparesis
- Active suicidal ideation or severe uncontrolled depression (requires monitoring plan)
- History of eating disorders (requires ED-informed care team)
Decision Framework
Ask yourself these four questions:
1. What's my medical upside?
Health risk reduction, not just aesthetics. What conditions might improve?
2. Can I tolerate weeks of GI symptoms + monitoring?
The adjustment period is real. How would it affect your work and life?
3. Can I sustain access financially for years if needed?
Given regain data, "the likely time horizon" may be years or indefinitely.
4. What's my plan if I must stop?
Because regain is common, starting without an exit strategy means walking into the biggest predictable downside without a plan.
Questions to Bring to Your Prescriber
- What symptoms mean call vs. urgent care?
- Can we slow titration if side effects hit?
- How will we protect lean mass?
- How will you monitor risk (eyes if diabetic retinopathy; dehydration/kidneys)?
- What's the plan if coverage ends?
The Unknowns: What We Don't Have Data On
Limited long-term data:
- Semaglutide for weight management: FDA approved 2021 (4 years of widespread use)
- Tirzepatide for weight management: FDA approved 2023 (2 years of data)
- We do not have 20-30 year safety data
Questions still being studied:
- Cancer risks over decades?
- Long-term bone density effects?
- Cardiovascular outcomes beyond 5 years?
- Gut microbiome impact?
You're accepting some uncertainty — true of any newer medication.
FAQ: Cons of GLP-1
Sources & Methodology
Evidence Hierarchy
- FDA prescribing information (primary source for side effect rates, warnings, contraindications)
- FDA safety communications (mental health updates, compounded/counterfeit warnings)
- Peer-reviewed clinical trials (stopping/regain data, body composition)
- Multi-society clinical guidance (perioperative management)
Source URLs
FDA Prescribing Information:
FDA Safety Communications:
Clinical Trials:
Surgery Guidance:
Update Log
- January 8, 2026: Initial publication
The Bottom Line
The cons of GLP-1 medications are real: GI side effects hit the majority of users, access remains a challenge, stopping usually means regaining weight, and rare serious risks require monitoring.
But "cons exist" doesn't mean "don't take it."
It means: go in with eyes open, make sure you're not contraindicated, and have a plan for side effects, cost, and long-term maintenance.
Bring this guide to your prescriber. Ask the hard questions. Make the decision that's right for you.